Phase III Study to Evaluate Efficacy and Safety of Andecaliximab With mFOLFOX6 as First-Line Treatment in Patients With Advanced Gastric or GEJ Adenocarcinoma (GAMMA-1).
Manish A ShahGyorgy BodokyAlexander StarodubDavid CunninghamDesmond YipZev A WainbergJohanna BendellDung ThaiJoyce HePankaj BhargavaJaffer A AjaniPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
The addition of ADX to mFOLFOX6 did not improve OS in unselected patients with untreated human epidermal growth factor receptor 2-negative gastric or GEJ adenocarcinoma.
Keyphrases
- epidermal growth factor receptor
- phase iii
- tyrosine kinase
- open label
- phase ii study
- squamous cell carcinoma
- advanced non small cell lung cancer
- clinical trial
- endothelial cells
- locally advanced
- metastatic colorectal cancer
- phase ii
- double blind
- placebo controlled
- induced pluripotent stem cells
- radiation therapy
- pluripotent stem cells